AbbVie’s Rinvoq passes PhIII AD test; Dicerna races Alnylam; New Sarepta gene & cell collab
→ Almost a year after it was approved for rheumatoid arthritis, AbbVie’s JAK inhibitor Rinvoq was shown for the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
